Corrigendum to Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int. 2021;99:314 –318

For the above-stated “point” article in the Controversies in Nephrology series, the authors regret that in Table 1 in the Renal outcome/endpoints column, for the GLP-1 receptor agonists ELIXA (2015) and EXSCEL (2017), post hoc was mischaracterized as secondary. The correct table appears below.
Source: Kidney International - Category: Urology & Nephrology Tags: Corrigenda Source Type: research